← Leaderboards
E. Ashley Moseman
Duke University
$4,103,637
Attributed
$4,415,555
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,415,555 · 6
By mechanism
R01$2,640,646 · 2
R21$1,774,909 · 4
Top collaborators
- James Culvin Morris2 shared
- Daniel Charles Whitehead2 shared
Most similar at Duke University
Same institution · by research overlap
- Herbert Kim Lyerly$48,598,090
- Oliver Michael Colvin$5,510,946
- Donald T. Fox$5,009,082
- Matthew Scott Kelly$2,764,525
- Hadiza S Kazaure$322,000
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsImmuneInfectionImmune ResponseTissuesBrainAlzheimer&AposCentral Nervous System InfectionsImmunityIn VivoAnimal ModelPathogenInvadedCell TypeNaegleria FowleriAmoeba GenusIn VitroNeuroprotectionLinkMouse ModelAntibodiesFosteringAnimalsEngineering
Grant awards (13)
Defining mucosal plasma cell origin, residence, and longevity in the upper airway$640,221
R01 · FY2025 · AI · contact PI
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions$402,500
R01 · FY2025 · NS · contact PI
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions$390,425
R01 · FY2024 · NS · contact PI
Enolase inhibitors as therapeutic leads for Naegleria fowleri infections$262,476
R21 · FY2024 · AI
T cell/astrocyte fusions as a novel form of trained immunity to infection$196,912
R21 · FY2024 · NS · contact PI
Defining the molecular and anatomical basis of the blood-olfactory barrier (BOB)$433,879
R21 · FY2023 · DC · contact PI
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions$402,500
R01 · FY2023 · NS · contact PI
T cell/astrocyte fusions as a novel form of trained immunity to infection$237,162
R21 · FY2023 · NS · contact PI
Enolase inhibitors as therapeutic leads for Naegleria fowleri infections$205,401
R21 · FY2023 · AI
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions$402,500
R01 · FY2022 · NS · contact PI
Infectious Influence: Using fate mapping to determine the impact of viral infection sites on Alzheimer's disease initiation$201,250
R21 · FY2022 · AG · contact PI
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions$402,500
R01 · FY2021 · NS · contact PI
Infectious Influence: Using fate mapping to determine the impact of viral infection sites on Alzheimer's disease initiation$237,829
R21 · FY2021 · AG · contact PI